1. Porter PL. Global trends in breast cancer incidence and mortality. Salud Pública Méx. 2009;51 Suppl 2:s141–6.
2. Sanchez-Zamorano LM, Flores-Luna L, Angeles-Llerenas A, et al. Healthy lifestyle on the risk of breast cancer. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2011.
3. Travis RC, Reeves GK, Green J, et al. Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study. Lancet. 2010;375(9732):2143–51.
4. Buck MB, Knabbe C. TGF-β signaling in breast cancer. Ann NY Acad Sci. 2006;1089:119–26.
5. ten Dijke P, Hill CS. New insights into TGF-β-Smad signalling. Trends Biochem Sci. 2004;29(5):265–73.
6. Moustakas A, Heldin CH. Non-Smad TGF-β signals. J Cell Sci. 2005;118(Pt 16):3573–84.
7. Zhang YE. Non-Smad pathways in TGF-β signaling. Cell Res. 2009;19(1):128–39.
8. Lee MK, Pardoux C, Hall MC, et al. TGF-β activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J. 2007;26(17):3957–67.
9. Bhowmick NA, Zent R, Ghiassi M, et al. Integrin β 1 signaling is necessary for transforming growth factor-β activation of p38MAPK and epithelial plasticity. J Biol Chem. 2001;276(50):46707–13.
10. Edlund S, Landstrom M, Heldin CH, et al. Transforming growth factor-β-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol Biol Cell. 2002;13(3):902–14.
11. Wilkes MC, Murphy SJ, Garamszegi N, et al. Cell-type-specific activation of PAK2 by transforming growth factor β independent of Smad2 and Smad3. Mol Cell Biol. 2003;23(23):8878–89.
12. Barcellos-Hoff MH, Akhurst RJ. Transforming growth factor-β in breast cancer: too much, too late. Breast Cancer Res. 2009;11(1):202.
13. Kleuser B, Malek D, Gust R, et al. 17-β-estradiol inhibits transforming growth factor-β signaling and function in breast cancer cells via activation of extracellular signal-regulated kinase through the G protein-coupled receptor 30. Mol Pharmacol. 2008;74(6):1533–43.
14. Hinshelwood RA, Huschtscha LI, Melki J, et al. Concordant epigenetic silencing of transforming growth factor-β signaling pathway genes occurs early in breast carcinogenesis. Cancer Res. 2007;67(24):11517–27.
15. Akhurst RJ, Derynck R. TGF-β signaling in cancer–a double- edged sword. Trends Cell Biol. 2001;11(11):S44–51.
16. Turashvili G, Bouchal J, Baumforth K, et al. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer. 2007;7:55.
17. Figueroa JD, Flanders KC, Garcia-Closas M, et al. Expression of TGF-β signaling factors in invasive breast cancers: relationships with age at diagnosis and tumor characteristics. Breast Cancer Res Treat. 2010;121(3):727–35.
18. Zhang S, Royer R, Li S, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol. 2011.
19. Li J, Zhu H, Chen T, et al. TGF-β1 and BRCA2 expression are associated with clinical factors in breast cancer. Cell Biochem Biophys. 2011.
20. Xu J, Lamouille S, Derynck R. TGF-β-induced epithelial to mesenchymal transition. Cell Res. 2009;19(2):156–72.
21. Miyazono K. Transforming growth factor-β signaling in epithelial-mesenchymal transition and progression of cancer. Proc Jpn Acad B Phys Biol Sci. 2009;85(8):314–23.
22. Massagué J. TGFβ in cancer. Cell. 2008;134(2):215–30.
23. ten Dijke P, Goumans MJ, Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis. 2008;11(1):79–89.
24. Flavell RA, Sanjabi S, Wrzesinski SH, et al. The polarization of immune cells in the tumour environment by TGF-β. Nature reviews. Immunology. 2010;10(8):554–67.
25. Buijs JT, Henriquez NV, van Overveld PG, et al. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res. 2007;67(18):8742–51.
26. Bos PD, Nguyen DX, Massagué J. Modeling metastasis in the mouse. Curr Opin Pharmacol. 2010;10(5):571–7.
27. Tsuji T, Ibaragi S, Hu GF. Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res. 2009;69(18):7135–9.
28. Grunert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nature reviews. Molec Cell Biol. 2003;4(8):657–65.
29. Padua D, Zhang XH, Wang Q, et al. TGF-β primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 2008;133(1):66–77.
30. Godde NJ, Galea RC, Elsum IA, et al. Cell polarity in motion: redefining mammary tissue organization through EMT and cell polarity transitions. J Mammary Gland Biol Neoplasia. 2010;15 (2):149–68.
31. Zavadil J, Bottinger EP. TGF-β and epithelial-to-mesenchymal transitions. Oncogene. 2005;24(37):5764–74.
32. Miettinen PJ, Ebner R, Lopez AR, et al. TGF-β induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol. 1994;127(6 Pt 2):2021–36.
33. Piek E, Moustakas A, Kurisaki A, et al. TGF-(β) type I receptor/ ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J Cell Sci. 1999;112(Pt 24):4557–68.
34. Lindley LE, Briegel KJ. Molecular characterization of TGFβ- induced epithelial-mesenchymal transition in normal finite life- span human mammary epithelial cells. Biochem Biophys Res Commun. 2010;399(4):659–64.
35. Jo M, Lester RD, Montel V, et al. Reversibility of epithelial- mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling. J Biol Chem. 2009;284(34):22825–33.
36. Trimboli AJ, Fukino K, de Bruin A, et al. Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res. 2008;68(3):937–45.
37. Turashvili G, Bouchal J, Ehrmann J, et al. Novel immunohisto- chemical markers for the differentiation of lobular and ductal invasive breast carcinomas. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. 2007;151(1):59–64.
38. Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 2010;15(2):117–34.
39. Christofori G. New signals from the invasive front. Nature. 2006;441(7092):444–50.
40. Vincent T, Neve EP, Johnson JR, et al. A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-β mediated epithelial-mesenchymal transition. Nat Cell Biol. 2009;11(8):943–50.
41. Thuault S, Valcourt U, Petersen M, et al. Transforming growth factor-β employs HMGA2 to elicit epithelial-mesenchymal transition. J Cell Biol. 2006;174(2):175–83.
42. Viloria-Petit AM, David L, Jia JY, et al. A role for the TGFβ- Par6 polarity pathway in breast cancer progression. Proc Natl Acad Sci USA. 2009;106(33):14028–33.
43. Shirakihara T, Horiguchi K, Miyazawa K, et al. TGF-β regulates isoform switching of FGF receptors and epithelial-mesenchymal transition. EMBO J. 2011;30(4):783–95.
44. Wendt MK, Smith JA, Schiemann WP. Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene. 2010;29(49):6485–98.
45. Micalizzi DS, Christensen KL, Jedlicka P, et al. The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-β signaling. J Clin Invest. 2009;119(9):2678–90.
46. Micalizzi DS, Wang CA, Farabaugh SM, et al. Homeoprotein Six1 increases TGF-β Type I receptor and converts TGF-β signaling from suppressive to supportive for tumor growth. Cancer Res. 2010;70(24):10371–80.
47. Deckers M, van Dinther M, Buijs J, et al. The tumor suppressor Smad4 is required for transforming growth factor β-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res. 2006;66(4):2202–9.
48. Thuault S, Tan EJ, Peinado H, et al. HMGA2 and Smads co- regulate SNAIL1 expression during induction of epithelial-to- mesenchymal transition. J Biol Chem. 2008;283(48):33437–46.
49. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10(5):593–601.
50. Bakin AV, Tomlinson AK, Bhowmick NA, et al. Phosphatidy- linositol 3-kinase function is required for transforming growth factor β-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem. 2000;275(47):36803–10.
51. de Graauw M, van Miltenburg MH, Schmidt MK, et al. Annexin A1 regulates TGF-β signaling and promotes metastasis formation of basal-like breast cancer cells. Proc Natl Acad Sci USA. 2010;107(14):6340–5.
52. Araki S, Eitel JA, Batuello CN, et al. TGF-β1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer. J Clin Investig. 2010;120(1):290–302.
53. Sabbah M, Prunier C, Ferrand N, et al. CCN5, a novel transcriptional repressor of transforming growth factor-β signaling pathway. Mol Cell Biol. 2011.
54. Mareel M, Oliveira MJ, Madani I. Cancer invasion and metastasis: interacting ecosystems. Virchows Archiv: An Inter- national Journal of Pathology. 2009;454(6):599–622.
55. Mareel M, Leroy A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev. 2003;83(2):337–76.
56. Hu M, Yao J, Carroll DK, et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell. 2008;13(5):394–406.
57. Luo YP, Zhou H, Krueger J, et al. The role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression. Oncogene. 2010;29 (5):662–73.
58. Mandal S, Johnson KR, Wheelock MJ. TGF-β induces formation of F-actin cores and matrix degradation in human breast cancer cells via distinct signaling pathways. Exp Cell Res. 2008;314(19):3478–93.
59. Wiercinska E, Naber HP, Pardali E, et al. The TGF-β/Smad pathway induces breast cancer cell invasion through the upregulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. Breast Cancer Res Treat. 2010.
60. Giampieri S, Manning C, Hooper S, et al. Localized and reversible TGF-β signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol. 2009;11 (11):1287–96.
61. McAllister SS, Weinberg RA. Tumor-host interactions: a far- reaching relationship. J Clin Oncol: Official Journal of the American Society of Clinical Oncology. 2010;28(26):4022–8.
62. Park CC, Bissell MJ, Barcellos-Hoff MH. The influence of the microenvironment on the malignant phenotype. Mol Med Today. 2000;6(8):324–9.
63. Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004;4(11):839–49.
64. Sieweke MH, Bissell MJ. The tumor-promoting effect of wounding: a possible role for TGF-β-induced stromal alterations. Crit Rev Oncog. 1994;5(2–3):297–311.
65. Shekhar MP, Pauley R, Heppner G. Host microenvironment in breast cancer development: extracellular matrix-stromal cell contribution to neoplastic phenotype of epithelial cells in the breast. Breast Cancer Res. 2003;5(3):130–5.
66. Olsen CJ, Moreira J, Lukanidin EM, et al. Human mammary fibroblasts stimulate invasion of breast cancer cells in a three- dimensional culture and increase stroma development in mouse xenografts. BMC Cancer. 2010;10:444.
67. Stuelten CH, Busch JI, Tang B, et al. Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-β mediated mechanism in a mouse xenograft model of breast cancer. PLoS ONE. 2010;5(3):e9832.
68. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449(7162):557–63.
69. Haviv I, Polyak K, Qiu W, et al. Origin of carcinoma associated fibroblasts. Cell Cycle. 2009;8(4):589–95.
70. Kojima Y, Acar A, Eaton EN, et al. Autocrine TGF-β and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci USA. 2010;107(46):20009–14.
71. Bhowmick NA, Chytil A, Plieth D, et al. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science. 2004;303(5659):848–51.
72. Cheng N, Bhowmick NA, Chytil A, et al. Loss of TGF-β type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-α-, MSP- and HGF- mediated signaling networks. Oncogene. 2005;24(32):5053–68.
73. Cheng N, Chytil A, Shyr Y, et al. Transforming growth factor-β signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion. Molec Cancer Res. 2008;6(10):1521–33.
74. Barcellos-Hoff MH, Ravani SA. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. 2000;60(5):1254–60.
75. Barcellos-Hoff MH. Radiation-induced transforming growth factor β and subsequent extracellular matrix reorganization in murine mammary gland. Cancer Res. 1993;53(17):3880–6.
76. Casey TM, Eneman J, Crocker A, et al. Cancer associated fibroblasts stimulated by transforming growth factor β1 (TGF- β1) increase invasion rate of tumor cells: a population study. Breast Cancer Res Treat. 2008;110(1):39–49.
77. Mantovani A, Marchesi F, Porta C, et al. Inflammation and cancer: breast cancer as a prototype. Breast. 2007;16 Suppl 2:S27–33.
78. Bierie B, Moses HL. TGF-β and cancer. Cytokine Growth Factor Rev. 2006;17(1–2):29–40.
79. Marigo I, Dolcetti L, Serafini P, et al. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev. 2008;222:162–79.
80. Gallina G, Dolcetti L, Serafini P, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Investig. 2006;116(10):2777–90.
81. Yang L, Huang J, Ren X, et al. Abrogation of TGF-β signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell. 2008;13(1):23–35.
82. Oliveira MJ, Van Damme J, Lauwaet T, et al. β-casein-derived peptides, produced by bacteria, stimulate cancer cell invasion and motility. EMBO J. 2003;22(22):6161–73.
83. Leask A, Abraham DJ. TGF-β signaling and the fibrotic response. FASEB J: Official Publication of the Federation of American Societies for Experimental Biology. 2004;18(7):816–27.
84. Kang Y, He W, Tulley S, et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA. 2005;102(39):13909–14.
85. Alarmo EL, Parssinen J, Ketolainen JM, et al. BMP7 influences proliferation, migration, and invasion of breast cancer cells. Cancer Lett. 2009;275(1):35–43.
86. Ketolainen JM, Alarmo EL, Tuominen VJ, et al. Parallel inhibition of cell growth and induction of cell migration and invasion in breast cancer cells by bone morphogenetic protein 4. Breast Cancer Res Treat. 2010;124(2):377–86.
87. Alarmo EL, Korhonen T, Kuukasjarvi T, et al. Bone morphogenetic protein 7 expression associates with bone metastasis in breast carcinomas. Ann Oncol: Official Journal of the European Society for Medical Oncology/ESMO. 2008;19(2):308–14.
88. Blair HC, Athanasou NA. Recent advances in osteoclast biology and pathological bone resorption. Histol Histopathol. 2004;19 (1):189–99.
89. Henderson MA, Danks JA, Slavin JL, et al. Parathyroid hormone-related protein localization in breast cancers predict improved prognosis. Cancer Res. 2006;66(4):2250–6.
90. Powell GJ, Southby J, Danks JA, et al. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res. 1991;51(11):3059–61.
91. Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Investig. 1996;98(7):1544–9.
92. Yin JJ, Selander K, Chirgwin JM, et al. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest. 1999;103(2):197–206.
93. Kakonen SM, Selander KS, Chirgwin JM, et al. Transforming growth factor-β stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem. 2002;277 (27):24571–8.
94. Evtimova V, Schwirzke M, Tarbe N, et al. Identification of breast cancer metastasis-associated genes by chip technology. Anticancer Res. 2001;21(6A):3799–806.
95. Watson MA, Ylagan LR, Trinkaus KM, et al. Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients. Clin Cancer Res: An Official Journal of the American Association for Cancer Research. 2007;13(17):5001–9.
96. Juarez P, Guise TA. TGF-β in cancer and bone: implications for treatment of bone metastases. Bone 2010.
97. Lu X, Wang Q, Hu G, et al. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev. 2009;23(16):1882–94.
98. Kang Y, Massagué J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell. 2004;118(3):277–9.
99. Dunn LK, Mohammad KS, Fournier PG, et al. Hypoxia and TGF-β drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS ONE. 2009;4(9):e6896.
100. Katoh M. Integrative genomic analyses of CXCR4: transcriptional regulation of CXCR4 based on TGFβ, Nodal, Activin signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and GFI1 transcription factors. Int J Oncol. 2010;36(2):415–20.
101. Shimo T, Kubota S, Yoshioka N, et al. Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer. J Bone Miner Res: The Official Journal of the American Society for Bone and Mineral Research. 2006;21(7):1045–59.
102. Alarmo EL, Kallioniemi A. Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis? Endocr-Relat Cancer. 2010;17(2):R123–39.
103. Johnson RW, Nguyen MP, Padalecki SS, et al. TGF-β promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical hedgehog signaling. Cancer Res. 2011;71(3):822–31.
104. Futakuchi M, Nannuru KC, Varney ML, et al. Transforming growth factor-β signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation. Cancer Sci. 2009;100(1):71–81.
105. Bierie B, Stover DG, Abel TW, et al. Transforming growth factor-β regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Cancer Res. 2008;68(6):1809–19.
106. Korpal M, Yan J, Lu X, et al. Imaging transforming growth factor-β signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med. 2009;15(8):960–6.
107. Petersen M, Pardali E, van der Horst G, et al. Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by 
108. Buijs JT, Que I, Lowik CW, et al. Inhibition of bone resorption and growth of breast cancer in the bone microenvironment. Bone. 2009;44(2):380–6.
109. Buijs JT, Henriquez NV, van Overveld PG, et al. TGF-β and BMP7 interactions in tumour progression and bone metastasis. Clin Exp Metastasis. 2007;24(8):609–17.
110. Buijs JT, Kuijpers CC, van der Pluijm G. Targeted therapy options for treatment of bone metastases; beyond bisphosphonates. Curr Pharm Des. 2010;16(27):3015–27.
111. Buijs JT, Petersen M, van der Horst G, et al. Bone morphogenetic proteins and its receptors; therapeutic targets in cancer progression and bone metastasis? Curr Pharm Des. 2010;16 (11):1291–300.
112. Kingsley LA, Fournier PG, Chirgwin JM, et al. Molecular biology of bone metastasis. Mol Cancer Ther. 2007;6 (10):2609–17.
113. McMahon S, Charbonneau M, Grandmont S, et al. Transforming growth factor β1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression. J Biol Chem. 2006;281(34):24171–81.
114. van der Pluijm G, Sijmons B, Vloedgraven H, et al. Monitoring metastatic behavior of human tumor cells in mice with species- specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases. J Bone Miner Res: The Official Journal of the American Society for Bone and Mineral Research. 2001;16 (6):1077–91.
115. Davies S, Jiang WG. ALCAM, activated leukocyte cell adhesion molecule, influences the aggressive nature of breast cancer cells, a potential connection to bone metastasis. Anticancer Res. 2010;30(4):1163–8.
116. Galaup A, Cazes A, Le Jan S, et al. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc Natl Acad Sci USA. 2006;103(49):18721–6.
117. Gupta GP, Perk J, Acharyya S, et al. ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci USA. 2007;104(49):19506–11.
118. Sadej R, Romanska H, Kavanagh D, et al. Tetraspanin CD151 regulates transforming growth factor β signaling: implication in tumor metastasis. Cancer Res. 2010;70(14):6059–70.